Best Genomics Companies in British Columbia, Canada
The 39 best Genomics companies in British Columbia, Canada in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Angle.
Our analysis of 50 Genomics companies
$7.8b in tracked funding; 84% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Genomics companies in British Columbia
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Angle Developer of cancer cell capture and analysis equipment | $81M | 49 mo ago | 176 | — | WordPressMySQLPHP+23 | Top 10M | — | — |
| 2 | ProNAi Therapeutics Developer of DNA-based gene therapies for cancer and other genetic diseases | $77M | 148 mo ago | — | Nick Glover President and CEO | — | — | — | — |
| 3 | Affinor Growers Developer of vertical farming technology and supplier of turnkey facilities | $38M | 46 mo ago | — | Nick Brusatore Founder & CEO | — | — | 17 patents Automated vertical farming towers for high‑density indoor horticulture and agriculture | — |
| 4 | Arbutus Bio Developer of nucleic acid-based therapeutics | $10M | 56 mo ago | 2 | — | DrupalPHPAmazon Web Services+20 | Top 10M | — | — |
| 5 | DelMar Pharmaceuticals Developer of drug candidates targeting orphan cancer indications | $8M | 72 mo ago | 3 | — | — | — | 24 patents Patents concentrated in health & consumer products | — |
| 6 | Biomark Diagnostics Provider of metabolomics-based diagnostics for cancer | $5M | 17 mo ago | 6 | — | WordPressMySQLPHP+21 | Top 50M | — | — |
| 7 | Molecular You Developer of personalized multi-omic digital health platform 53Talent top 28%Innovation top 31%Patents top 31%Moat top 32% All 9 signals ▾Talenttop 28% Innovationtop 31% Patentstop 31% Moattop 32% Techtop 37% Fundingtop 47% Productbottom 48% Globalbottom 36% Marketbottom 33% Talent: Analyst team rating 4/5 Innovation: 24 patents (top 39% of patent-holders) · 19 filings since 2022 vs 5 in 2017-21 rank vs industry peers · Fliar Intelligence Index 53/100 | $5M | 12 mo ago | 28 | — | WordPressApple iCloud MailGoogle Workspace+28 | Top 10M | 24 patents Molecular diagnostics and personalized therapy for cancer, neurodegenerative, and autism disorders | — |
| 8 | Renaissance BioScience Developer of bioengineering technology for agriculture, food, health, and industrial markets | $5M | 30 mo ago | 22 | John Husnik Co-Founder & CEO | NginxGSAPjQuery+12 | Top 50M | 30 patents Engineered yeast for asparagine reduction in food and RNA bioactive molecule production | — |
| 9 | GenXys Provider of pharmacogenetic testing and a medication decision support system | $4M | 66 mo ago | 17 | Martin Dawes Founder & CEO | WordPressMySQLPHP+34 | Top 50M | — | — |
| 10 | Med BioGene Provider of genomics-based test for the detection of early-stage lung cancer | $3M | — | 7 | — | — | — | — | — |
| 11 | Citation Growth Online retailer of domain names with various purchasing and financing options | $1M | 82 mo ago | — | Rahim Mohamed Co-CEO | — | — | — | — |
| 12 | Fusion Genomics Provider of molecular diagnostics and cloud-based analytic tools | $1M | 79 mo ago | 12 | Greg Stazyk Co Founder | WordPressMySQLPHP+20 | Top 10M | 5 patents AI-driven design and synthesis of molecular probes for genomic diagnostics | — |
| 13 | Augurex Developer of diagnostic tests to detect autoimmune and chronic diseases | $978K | 186 mo ago | 20 | — | WordPressMySQLPHP+26 | Top 50M | — | — |
| 14 | Novation Pharmaceuticals Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform | $626K | 18 mo ago | — | Dominique Cheneval President and Co-Founder | — | — | 21 patents Small‑molecule benzopyran therapeutics and assays targeting mRNA stability modulation | — |
| 15 | Creatus Biosciences Developer of biochemicals using synthetic biology | $320K | 60 mo ago | 6 | — | — | — | 34 patents Engineered yeast strains for enhanced xylose uptake and xylitol production | — |
| 16 | Microbiome Insights Provider of microbiome analysis solutions for academic and industrial researchers | $303K | 90 mo ago | 13 | Malcolm Kendall Co-founder & CEO | WordPressMySQLPHP+39 | Top 50M | — | — |
Top 12 Genomics companies in British Columbia
#1
Series A · Vancouver, British Columbia · founded 2014 · 28 employees$5Mraised▾
Developer of personalized multi-omic digital health platform. and recommendations for health interventions by interpreting a person's genetic, metabolite, protein, and microbial molecular profiles. The company's platform is called MYHealthIntelligence, and it generates predictive and prescriptive health insights and personalized action plans covering various organs/health systems and diseases. The platform allows users to securely store, share, navigate and analyze their data on its cloud platform, and allows medical practitioners to create proactive and targeted plans.
- Aug 2025Series A$5M
#2
Public · Richmond, British Columbia · founded 2007 · 6 employees$5.3Mraised▾
Provider of metabolomics-based diagnostics for cancer. Its proprietary technology involves measurement of levels of aceylated levels of the drug Amantadine, administered to patients prior to testing. Acetylation occurs due to the presence of Spermidine N-Acetyl Transferase (SSAT),which is elevated in many cancers including lung, breast, melanoma, GI and others.
- Mar 2025Post IPO$2.5M
- Apr 2024Grant (prize money)$290K
- May 2022Post IPO$1.2M
- Jun 2021Grant (prize money)$683.4K
#3
Funding Raised · Burnaby, British Columbia · founded 1999$625.5Kraised▾
Developer of small molecules to modulate intracellular messenger RNA using a proprietary discovery platform. The company is using its proprietary technology Quest to discover small molecules. The technology involves identification of mRNA stability regulatory elements (SCEs); cloning of the target SCE into a relevant diseased cell and then the production of stable cell line; screening of compound libraries.
- Mar 2025Grant (prize money)$625.5K
#4
Public · Surrey, British Columbia · founded 1994 · 176 employees$81.4Mraised▾
Developer of cancer cell capture and analysis equipment. The company uses liquid biopsy technology and develops Parsortix PC1 Clinical System a medical device for the capture and harvest of intact circulating tumor cells (CTCs) from metastatic breast cancer (MBC) patient blood for user-validated analysis.
- Jul 2022Post IPO$23.7M
- Oct 2020Post IPO$25.9M
- Jun 2018Post IPO$14.8M
- Jan 2018Grant (prize money)$557.5K
#5
Public · Vancouver, British Columbia · founded 1996$37.6Mraised▾
Developer of vertical farming technology and supplier of turnkey facilities. The company provides greenhouses, growing towers, automation, and cultivation processes. It has patents for its growing towers. The company also has patent pending automated lettuce line production technology ready for commercial pilot.
- Oct 2022Post IPO$124K
- Jun 2022Post IPO—
- Jan 2022Post IPO$365.1K
- Mar 2021Post IPO$789.6K
#6
Series A · Vancouver, British Columbia · founded 2013 · 22 employees$5Mraised▾
Developer of bioengineering technology for agriculture, food, health, and industrial markets. It creates products and solutions using whole organism and gene-targeted engineering. The technology benefits multiple industries, including biopesticides, animal wellness, bakery, coffee, alcoholic beverages, probiotics, nutritional supplements, flavors, fragrances, and biofuels.
- Feb 2024Grant (prize money)$172.3K
- Nov 2021Series A$5M
- Jun 2017Grant (prize money)$370K
#7
Deadpooled · Vancouver, British Columbia · founded 2004$77.5Mraised▾
Developer of DNA-based gene therapies for cancer and other genetic diseases
- Apr 2014Series D$59.5M
- Jan 2014Series C$12M
- Jun 2013Conventional Debt$4.3M
- Dec 2010Series B$1.7M
#8
Public · Burnaby, British Columbia · founded 1992 · 2 employees$10Mraised▾
Arbutus Bio is a developer of nucleic acid-based therapeutics. The company's proprietary Lipid Nanoparticle (LNP) technology encapsulates siRNA and other RNA-based therapeutics in lipids to prevent in vivo degradation. Its lead program is a siRNA-based therapeutic against the Hepatitis B Virus (HBV) that is being designed to arrest replication of the virus.
- Dec 2021Post IPO$55M
- Jan 2018Post IPO$66.4M
- Sep 2017Post IPO$50M
- Mar 2008Series A$10M
#9
Public · Vancouver, British Columbia · founded 2010 · 3 employees$7.9Mraised▾
Developer of drug candidates targeting orphan cancer indications. The company's lead product candidate, VAL-083, is small molecule chemotherapy for the treatment of refractory glioblastoma multiforme (GBM), the most common and aggressive form of brain cancer. The company is also exploring VAL-083 as a therapy for front-line GBM and solid tumors including non-small cell lung cancer and ovarian cancer.
- Aug 2020Post IPO—
- Jan 2017Grant (prize money)$296K
- May 2016Post IPO$5.6M
- Aug 2015Post IPO$2.6M
#10
Seed · Vancouver, British Columbia · founded 2014 · 17 employees$4.3Mraised▾
Provider of pharmacogenetic testing and a medication decision support system. The company offers TreatGxPlus, a home collection kit that can be ordered by consumers for Pharmacogenetic testing, and the company provides a report on genetic variants that may affect body responses to medications. These results can be shared with a healthcare professional to facilitate shared decision-making on medication options between the user and the healthcare professional. The company also offers TreatGx, a medication decision support tool for healthcare professionals that provides personalized medication options by combining pharmacogenetic and medical information with the best clinical evidence.
- Mar 2021Seed$3M
- May 2020Seed—
- Apr 2019Seed$1.3M
#11
Public · Vancouver, British Columbia · founded 2002 · 7 employees$3.1Mraised▾
Provider of genomics-based test for the detection of early-stage lung cancer. The company has developed GeneFx Lung (formerly LungExpress Dx), a proprietary 15 gene expression-based test for early-stage non-small-cell lung cancer (NSLC). It claims that the test provides better-informed and personalized treatment decisions to assist patients in the selection of adjuvant chemotherapy. It has a partnership with Helomics (Precision Therapeutics) for the global commercialization of GeneFx Lung.
- Post IPO$3.1M
#12
Public · Kelowna, British Columbia · founded 2019$1.1Mraised▾
Online retailer of domain names with various purchasing and financing options. It provides domain name registration services. The business facilitates domain acquisition with options for payment plans and outright purchase. It offers domain management tools and customer support.
- Oct 2019Post IPO$1.1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Genomics coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Canada
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,804 Canada-affiliated papers.
- Ministry of Education187
- University of Toronto155
- University of British Columbia117
- McGill University108
- Ministry of Agriculture72
- Gene8→75
- Genome16→64
- Transcriptome2→41
- Immune system1→24
- Drug discovery2→21
- Microbiome1→19
- Gut flora1→18
- Metabolomics2→17
- Genome4→18
- Drug discovery1→10
- Disease2→55
- Clinical trial1→24
- Immune system1→19
- Gene1→19
- Epigenetics1→13
Where bioinformatics is researched across Canada
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.